Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

5 months ago 19
Read Entire Article
  1. Homepage
  2. Finance
  3. Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Related

PT Perusahaan Gas Negara stock maintains Overweight rating at JPMorgan

PT Perusahaan Gas Negara stock maintains Overweight rating a...

54 minutes ago 0
Sampo continues share buyback program with €2.6 million purchase

Sampo continues share buyback program with €2.6 million purc...

54 minutes ago 0
Kotak downgrades Shriram Finance stock rating to Add from Buy despite price target increase

Kotak downgrades Shriram Finance stock rating to Add from Bu...

54 minutes ago 0

Trending

1. salma hayek
2. dubai
3. philippines
4. tom hardy
5. sofia vergara
6. las vegas weather
7. car accident lawyers
8. pg&e
9. car accident attorney
10. latto

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

11 months ago 638
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

9 months ago 512
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

9 months ago 374
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

9 months ago 331
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

11 months ago 328
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved